The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders
Abstract
In this report, recommendations for the pharmacological treatment of anxiety and obsessive-compulsive disorders are presented, based on available randomized, placebo- or comparator-controlled clinical studies. Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for panic disorder. Tri2-cyclic antidepressants (TCAs) are equally effective, but they are less well tolerated than the SSRIs. In treatment-resistant cases, benzodiazepines like alprazolam may be used when the patient does not have a history of dependency and tolerance. Due to possible serious side effects and interactions with other drugs and food components, the irreversible monamine oxidase inhibitor (MAOI) phenelzine should be used only when first-line drugs have failed. In generalised anxiety disorder, venlafaxine and SSRIs can be recommended, while buspirone and imipramine may be alternatives. For social phobia, SSRIs are recommended for the first line, and MAOIs, moclobemide and benzodiazepines as second line. Obsessive-compulsive disorder is best treated with SSRIs or clomipramine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Clark, D. M., Salkovskis, P. M., Hackmann, A., Middleton, H., Anastasiades, P., & Gelder, M. (1994) · British Journal of Psychiatry · doi:10.1192/bjp.164.6.759 · Cited by 673
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Sartorius, N., Üstün, T. B., Lecrubier, Y., & Wittchen, H.-U. (1996) · British Journal of Psychiatry · doi:10.1192/s0007125000298395 · Cited by 541 · cited 1×
“In primary care, anxiety disorders are usually underdiagnosed (Sartorius et al 1996) or recognized only years after onset.”
BackgroundClomipramine Treatment of Obsessive-Compulsive Disorder: I. A Controlled Clinical Trial
Thorén, P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780240079009 · Cited by 497
Research works printed but not linked: 316
- AACAP, 1998, J Am Acad Child Adolesc Psychiatry, 37, 27S, 10.1097/00004583-199810001-00003 · DOI · Paper page
- Agid O, 1999, J Clin Psychiatry, 60, 55, 10.4088/JCP.v60n0112d · DOI
- Allgulander C, 1999, Acta Psychiatr Scand, 100, 193, 10.1111/j.1600-0447.1999.tb10845.x · DOI
- Altamura A C., 1999, Int Clin Psychopharmacol, 14, 239, 10.1097/00004850-199907000-00006 · DOI
- Altshuler L L., 2001, Postgrad Med, 1
- Amore M, 1999, Hum Psychopharmacol Clin Exp, 14, 429, 10.1002/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.0.CO;2-3 · DOI
- Amore M, 1999, Hum Psychopharmacol Clin Exp, 14, 435, 10.1002/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B · doi:10.1002/(sici)1099-1077(199908)14:6<435::aid-hup109>3.0.co;2-b
- Andersch S, 1991, Acta Psychiatr Scand Suppl, 365, 18, 10.1111/j.1600-0447.1991.tb03097.x · DOI
- Ansseau M, 1991, Psychopharmacology, 104, 439, 10.1007/BF02245646 · DOI
- APA, 1994, American Psychiatric Association. Diagnostic and Statistical Manual of Mental DisordersFourth Edition
- APA, 1998, Am J Psychiatry, 155, 1, 10.1176/ajp.155.1.1 · DOI · Paper page
- Atmaca M, 2002, Int Clin Psychopharmacol, 17, 115, 10.1097/00004850-200205000-00004 · DOI
- Austin M PV, 1998, Med J Aust, 169, 428, 10.5694/j.1326-5377.1998.tb126837.x · DOI
- Bakish D, 1996, Psychopharmacol Bull, 32, 135
- Bakker A, 1999, J Clin Psychiatry, 60, 831, 10.4088/JCP.v60n1205 · DOI
- Baldwin D, 1999, Br J Psychiatry, 175, 120, 10.1192/bjp.175.2.120 · DOI · Paper page
- Ballenger J C, 1999, Biol Psychiatry, 46, 1579, 10.1016/S0006-3223(99)00220-6 · DOI
- Ballenger J C., 1998, J Clin Psychiatry, 59, 47, 10.4088/JCP.v59n0201 · DOI
- Ballenger J C., 1998, J Clin Psychiatry, 59, 54
- Ballenger J C., 1998, Am J Psychiatry, 155, 36, 10.1176/ajp.155.1.36 · DOI · Paper page
- Ballenger J C., 2000, J Clin Psychiatry, 61, 60
- Ballenger J C., 2001, J Clin Psychiatry, 62, 53
- Bandelow B, 1995, Eur Arch Psychiatry Clin Neurosci, 245, 165, 10.1007/BF02193090 · DOI
- Bandelow B, 1999, Hogrefe & Huber PublishersPanic and Agoraphobia Scale (PAS)
- Bandelow B, 2002, J Handbook on Depression and Anxiety
- Barlow D H, 1997, J Clin Psychiatry, 58, 32, 10.4088/JCP.v58n0106e · DOI
- Barlow D, 1989, Behav Ther, 20, 261, 10.1016/S0005-7894(89)80073-5 · DOI · Paper page
- Beauclair L, 1994, J Clin Psychopharmacol, 14, 111, 10.1097/00004714-199404000-00005 · DOI
- Beck A T., 1985, Anxiety disorders and phobias—a cognitive perspective
- Beck A T., 1992, Am J Psychiatry, 149, 778, 10.1176/ajp.149.6.778 · DOI · Paper page
- Benjamin J, 1995, Am J Psychiatry, 152, 1084, 10.1176/ajp.152.7.1084 · DOI · Paper page
- Benjamin J, 2000, Psychopharmacology (Berl), 149, 194, 10.1007/s002130000372 · DOI
- Bezchlibnyk‐Butler K Z., 2001, Clinical handbook of psychotropic drugs
- Bisserbe J, 1997, Eur Psychiatry, 12, 82, 10.1016/S0924-9338(97)89646-0 · DOI
- 10.1001/archpsyc.1993.01820130046008 · DOI · Paper page
- Blier P, 1996, Int Clin Psychopharmacol, 11, 37, 10.1097/00004850-199603000-00005 · DOI
- 10.1192/bjp.179.1.23 · DOI · Paper page
- Bogetto F, 2000, Psychiatry Res, 96, 91, 10.1016/S0165-1781(00)00203-1 · DOI
- Borkovec T D., 1996, Long‐term treatment for the anxiety disorders, 171
- Bouwer C, 1998, J Affect Disord, 49, 79, 10.1016/S0165-0327(97)00182-1 · DOI
- Boyer W, 1995, Int Clin Psychopharmacol, 10, 45, 10.1097/00004850-199503000-00006 · DOI · Paper page
- Boyer W F., 1993, Int Clin Psychopharmacol, 8, 173, 10.1097/00004850-199300830-00006 · DOI
- Bradwejn J, 1993, Can J Psychiatry, 38, S109
- Brady K T., 1993, Psychiatr Q, 64, 135, 10.1007/BF01065866 · DOI
- Brady K, 2000, Jama, 283, 1837, 10.1001/jama.283.14.1837 · DOI · Paper page
- Braun P, 1990, J Clin Psychiatry, 51, 236
- Brom D, 1989, J Consult Clin Psychol, 57, 607, 10.1037/0022-006X.57.5.607 · doi:10.1037/0022-006x.57.5.607 · Paper page
- Bystritsky A, 1994, Anxiety, 1, 287, 10.1002/anxi.3070010608 · DOI
- Bystritsky A, 1999, Depress Anxiety, 10, 137, 10.1002/(SICI)1520-6394(1999)10:3<137::AID-DA8>3.0.CO;2-7 · doi:10.1002/(sici)1520-6394(1999)10:3<137::aid-da8>3.0.co;2-7
- Cahill S P., 1999, J Anxiety Disord, 13, 5, 10.1016/S0887-6185(98)00039-5 · DOI
- 10.3109/10401239909147053 · doi:10.3109/10401239909147053
- Cassano G B., 1988, J Affect Disord, 14, 123, 10.1016/0165-0327(88)90054-7 · DOI
- Charney D, 1999, Neurobiology of mental illness, 494
- Charney D S., 1989, J Clin Psychiatry, 50, 418
- Charney D S., 1986, J Clin Psychiatry, 47, 580
- Chouinard G, 1990, Psychopharmacol Bull, 26, 279
- Clark D M., 1995, Social phobia: Diagnosis, assessment, and treatment, 69
- Clomipramine Collaborative Study Group, 1991, Arch Gen Psychiatry, 48, 730, 10.1001/archpsyc.1991.01810320054008 · DOI · Paper page
- CNCPS, 1992, Br J Psychiat, 160, 191, 10.1192/bjp.160.2.191 · DOI · Paper page
- Cohen S D., 1984, Br J Psychiatry, 144, 276, 10.1192/bjp.144.3.276 · DOI
- Connor K M., 1998, Biol Psychiatry, 44, 1286, 10.1016/S0006-3223(98)00285-6 · DOI
- Connor K M., 1999, Br J Psychiatry, 175, 17, 10.1192/bjp.175.1.17 · DOI · Paper page
- Cottraux J, 1995, Br J Psychiatry, 167, 635, 10.1192/bjp.167.5.635 · DOI
- Cournoyer J, 1986, Can J Psychiatry, 31, 335, 10.1177/070674378603100410 · DOI
- Cowley D S., 1997, J Clin Psychiatry, 58, 555, 10.4088/JCP.v58n1208 · DOI
- Dannon P N., 2000, Eur Neuropsychopharmacol, 10, 165, 10.1016/S0924-977X(00)00065-1 · DOI
- Davidson J, 1990, Arch Gen Psychiatry, 47, 259, 10.1001/archpsyc.1990.01810150059010 · DOI · Paper page
- Davidson J RT, 1993, J Clin Psychopharmacol 1, 3, 423
- Davidson J R., 1998, J Clin Psychopharmacol, 18, 93, 10.1097/00004714-199802000-00020 · DOI
- Davidson J R., 1999, J Clin Psychiatry, 60, 528, 10.4088/JCP.v60n0805 · DOI · Paper page
- Davidson J, 2001, Am J Psychiatry, 158, 1974, 10.1176/appi.ajp.158.12.1974 · DOI · Paper page
- Davidson J R., 2001, Arch Gen Psychiatry, 58, 485, 10.1001/archpsyc.58.5.485 · DOI · Paper page
- DeMartinis N A., 1996, J Clin Psychiatry, 57, 245
- den Boer J A., 1990, Psychopharmacology Berl, 102, 85, 10.1007/BF02245749 · DOI · Paper page
- GeissDeVeaugh J, 1989, Psychopharmacol Bull, 25, 36
- De Veaugh‐Geiss J, 1992, J Am Acad Child Adolesc Psychiatry, 31, 45, 10.1097/00004583-199201000-00008 · DOI · Paper page
- Dunner D L., 1986, J Clin Psychiatry, 47, 458
- DuPont R L., 1996, Anxiety, 2, 167, 10.1002/(SICI)1522-7154(1996)2:4<167::AID-ANXI2>3.0.CO;2-L · DOI · Paper page
- Dyukova G M., 1992, Neurosci Behav Physiol, 22, 343, 10.1007/BF01182877 · DOI
- Elie R, 1984, J Clin Psychopharmacol, 4, 125, 10.1097/00004714-198406000-00002 · DOI
- Emslie C, 2000, Acta Psychiatrica Scandinavica, 101, 26, 10.1111/j.1600-0447.2000.tb10945.x · DOI
- Enkelmann R, 1991, Psychopharmacology, 105, 428, 10.1007/BF02244440 · DOI
- Ericson A, 1999, Eur J Clin Pharmacol, 55, 503, 10.1007/s002280050664 · DOI · Paper page
- Expert Consensus Panel for Obsessive‐Compulsive Disorder, 1997, J Clin Psychiatry, 58, 2
- Facorro B C., 1997, Actas Luso‐Españolas de Neurologia Psiquiatria y Ciencias Afines, 25, 61
- Fallon B A., 1998, Arch Gen Psychiatry, 55, 918, 10.1001/archpsyc.55.10.918 · DOI
- Feighner J P., 1982, J Clin Psychiatry, 43, 103
- Ferreri M, 1994, Encéphale, 20, 785
- Feske U, 1997, J Consult Clin Psychol, 65, 1026, 10.1037/0022-006X.65.6.1026 · doi:10.1037/0022-006x.65.6.1026
- Fesler F A, 1991, J Clin Psychiatry, 52, 361
- FitzGerald K D., 1999, J Child Adolesc Psychopharmacol, 9, 115, 10.1089/cap.1999.9.115 · DOI
- Foa E B, 2000, J Clin Psychiatry, 61, 43
- Fontaine R, 1983, J Clin Psychopharmacol, 3, 80, 10.1097/00004714-198304000-00005 · DOI
- Francobandiera G, 2001, Can J Psychiatry, 46, 356, 10.1177/070674370104600408 · DOI
- Frank J B., 1988, Am J Psychiatry, 145, 1289, 10.1176/ajp.145.10.1289 · DOI · Paper page
- Furukawa T A., Streiner D L., Young L T. 2002, Antidepressant and benzodiazepine for major depression (Cochrane Review) Cochrane Database Syst Rev CD001026 · DOI · Paper page
- Fux M, 1996, Am J Psychiatry, 153, 1219, 10.1176/ajp.153.9.1219 · DOI · Paper page
- Gelenberg A J., 2000, Jama, 283, 3082, 10.1001/jama.283.23.3082 · DOI · Paper page
- Geller D A., 2001, J Am Acad Child Adolesc Psychiatry, 40, 773, 10.1097/00004583-200107000-00011 · DOI · Paper page
- Goddard A W., 2001, Arch Gen Psychiatry, 58, 681, 10.1001/archpsyc.58.7.681 · DOI
- Goldstein A J., 2000, J Consult Clin Psychol, 68, 947, 10.1037/0022-006X.68.6.947 · DOI
- Goldstein D J., 1999, Hum Psychopharmacol Clin Exp, 14, 319, 10.1002/(SICI)1099-1077(199907)14:5<319::AID-HUP99>3.0.CO;2-D · DOI
- Goodman W K., 1989, Arch Gen Psychiatry, 46, 36, 10.1001/archpsyc.1989.01810010038006 · DOI · Paper page
- Goodman W K., 1996, Int Clin Psychopharmacol, 11, 21, 10.1097/00004850-199603000-00003 · DOI
- Gorman J M., 1987, J Clin Psychopharmacol, 7, 329, 10.1097/00004714-198710000-00007 · DOI · Paper page
- Gorman J M., 2000, Am J Psychiatry, 157, 493, 10.1176/appi.ajp.157.4.493 · DOI · Paper page
- Gould R A., 1993, Behav Ther, 24, 241, 10.1016/S0005-7894(05)80266-7 · DOI · Paper page
- Greist J H., 1998, Br J Psychiatry Suppl, 35, 64, 10.1192/S0007125000297912 · DOI
- Greist J, 1995, Arch Gen Psychiatry, 52, 289, 10.1001/archpsyc.1995.03950160039008 · DOI · Paper page
- Greist J H., 1995, Arch Gen Psychiatry, 52, 53, 10.1001/archpsyc.1995.03950130053006 · DOI · Paper page
- Hair T, 2000, Int J Neuropsychopharmacol, 3, S227
- Hamner M B., 1998, Int Clin Psychopharmacol, 13, 233, 10.1097/00004850-199809000-00008 · DOI
- Harvey A G., 1995, Psychiatr Clin North Am, 18, 859, 10.1016/S0193-953X(18)30027-3 · DOI
- Heimberg R G, 1995, Social Phobia—clinical and research perspectives, 293
- 10.1016/S0006-3223(99)00011-6 · DOI · Paper page
- Hertzberg M A., 2000, Ann Clin Psychiatry, 12, 101, 10.3109/10401230009147096 · DOI · Paper page
- Hoehn‐Saric R, 1988, J Clin Psychiatry, 49, 293
- 10.1097/00004714-199310000-00004 · DOI
- Hoehn‐Saric R, 2000, Arch Gen Psychiatry, 57, 76, 10.1001/archpsyc.57.1.76 · DOI
- Hoffart A, 1990, Psychotherapy, 27, 210, 10.1037/0033-3204.27.2.210 · DOI
- Hohagen F, 1998, Br J Psychiatry Suppl, 35, 71, 10.1192/S0007125000297924 · DOI · Paper page
- Hollon S, 1999, Psychotherapy Indications and Outcomes, 343
- IMCTGMSP, 1997, Eur Arch Psychiatry Clin Neurosci, 247, 71, 10.1007/BF02900196 · DOI
- Jacobson A F., 1985, Pharmacotherapy, 5, 290, 10.1002/j.1875-9114.1985.tb03430.x · DOI
- James I, 1984, Am Heart J, 108, 1150, 10.1016/0002-8703(84)90599-4 · DOI
- James I M., 1983, J R Soc Med, 76, 194, 10.1177/014107688307600308 · DOI
- Jenike M A., 1991, J Clin Psychiatry, 52, 13
- Jenike M A., 1997, Am J Psychiatry, 154, 1261, 10.1176/ajp.154.9.1261 · DOI
- Jetty P V., 2001, Psychiatr Clin North Am, 24, 75, 10.1016/S0193-953X(05)70207-0 · DOI
- Johnston D, 1988, Arch Gen Psychiat, 45, 453, 10.1001/archpsyc.1988.01800290073009 · DOI
- Kasper S, 2002, A placebo‐controlled study of pregabalin and venlafaxine treatment of GAD Poster
- Kasper S, 2002, Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. Poster
- Katz R J., 1990, Biol Psychiatry, 28, 401, 10.1016/0006-3223(90)90408-T · DOI · Paper page
- Katzelnick D J., 1995, Am J Psychiatry, 152, 1368, 10.1176/ajp.152.9.1368 · DOI · Paper page
- Kawahara T, 2000, Psychiatry Clin Neurosci, 54, 599, 10.1046/j.1440-1819.2000.00760.x · DOI
- Keck P E., 1993, Biol Psychiatry, 33, 542, 10.1016/0006-3223(93)90010-B · DOI
- Kessler R C., 1994, Arch Gen Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
- Klein D, 1964, Psychopharmacol, 5, 397, 10.1007/BF02193476 · DOI · Paper page
- Klein D F, 1998, Treatment, 1, 1
- Klein D F, 2000, Am J Psychiatry, 157, 1204, 10.1176/appi.ajp.157.8.1204 · DOI
- Klerman G L., 1991, Jama, 265, 742, 10.1001/jama.1991.03460060074027 · DOI · Paper page
- Klosko J S., 1990, J Consult Clin Psychol, 58, 77, 10.1037/0022-006X.58.1.77 · DOI · Paper page
- Kobak K A., 2002, J Clin Psychopharmacol, 22, 257, 10.1097/00004714-200206000-00005 · DOI
- Koran L M., 1997, Am J Psychiatry, 154, 396, 10.1176/ajp.154.3.396 · DOI
- Koran L M., 2000, J Clin Psychiatry, 61, 514, 10.4088/JCP.v61n0709 · DOI
- Kosten T R., 1991, J Nerv Ment Dis, 179, 366, 10.1097/00005053-199106000-00011 · DOI · Paper page
- Kronig M H., 1999, J Clin Psychopharmacol, 19, 172, 10.1097/00004714-199904000-00013 · DOI
- Krüger M B., 1999, Eur Archives Psychiatry Clin Neurosci, 249, S19, 10.1007/PL00014163 · DOI
- Lader M, 1998, Psychopharmacology‐Berl, 139, 402, 10.1007/s002130050731 · DOI
- Laegreid L, 1990, Dev Med Child Neural, 32, 432, 10.1111/j.1469-8749.1990.tb16962.x · DOI
- Lecrubier Y, 1997, Acta Psychiatr Scand, 95, 145, 10.1111/j.1600-0447.1997.tb00388.x · DOI
- Leonard H L., 1989, Arch Gen Psychiatry, 46, 1088, 10.1001/archpsyc.1989.01810120030006 · DOI · Paper page
- Leonard H L., 1994, J Am Acad Child Adolesc Psychiatry, 33, 792, 10.1097/00004583-199407000-00003 · DOI
- Lepola U, 1990, Human Psychopharmacol, 5, 159, 10.1002/hup.470050209 · DOI
- Lepola U M., 1998, J Clin Psychiatry, 59, 528, 10.4088/JCP.v59n1006 · DOI
- Li D, 2001, J Psychiatry Neurosci, 26, 190
- Lidren D M., 1994, J Consult Clin Psychol, 62, 865, 10.1037/0022-006X.62.4.865 · DOI · Paper page
- Liebowitz M R, 1987, Mod Probl Pharmacopsychiatry, 22, 141, 10.1159/000414022 · DOI · Paper page
- Liebowitz M R., 1988, J Clin Psychiatry, 49, 252
- Liebowitz M R., 1999, Depress Anxiety, 10, 89, 10.1002/(SICI)1520-6394(1999)10:3<89::AID-DA1>3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
- Lipper S, 1986, Psychosomatics, 27, 849, 10.1016/S0033-3182(86)72590-5 · DOI · Paper page
- Livingston M G, 1994, Br J Hosp Med, 51, 281
- Loerch B, 1999, Br J Psychiatry, 174, 205, 10.1192/bjp.174.3.205 · DOI
- Londborg P D., 1998, Br J Psychiatry, 173, 54, 10.1192/bjp.173.1.54 · DOI
- Londborg P D., 2001, J Clin Psychiatry, 62, 325, 10.4088/JCP.v62n0503 · DOI
- Lopez‐Ibor J J., 1996, Eur Neuropsychopharmacol, 6, 111, 10.1016/0924-977X(95)00071-V · DOI
- Lum M, 1990, Biol Psychiatry, 27, 164A
- Lydiard R B., 1992, J Clin Psychopharmacol, 12, 96, 10.1097/00004714-199204000-00004 · DOI
- Lydiard R B., 1997, J Clin Psychiatry, 58, 11, 10.4088/JCP.v58n1104 · DOI
- Mahe V, 2000, Int Clin Psychopharmacol, 15, 99, 10.1097/00004850-200015020-00006 · DOI
- Marazziti D, 1999, Am J Psychiatry, 156, 1834, 10.1176/ajp.156.11.1834-a · doi:10.1176/ajp.156.11.1834-a
- Marazziti D, 2001, Int Clin Psychopharmacol, 16, 215, 10.1097/00004850-200107000-00005 · DOI
- March J S., 1998, Jama, 280, 1752, 10.1001/jama.280.20.1752 · DOI · Paper page
- Markovitz P J., 1990, Am J Psychiatry, 147, 798, 10.1176/ajp.147.6.798 · DOI
- Marks I, 1994, Int Acad Biomed Drug Res, 8, 122
- Marks I M, 1987, Fears, phobias and rituals
- Marks I, 1983, Arch Gen Psychiat, 40, 153, 10.1001/archpsyc.1983.01790020047004 · DOI · Paper page
- Marmar C R., 1996, J Clin Psychiatry, 57, 66
- Marshall R D., 1998, J Clin Psychopharmacol, 18, 10, 10.1097/00004714-199802000-00003 · DOI
- Mavissakalian M, 1983, Psychopharmacol Bull, 19, 116
- Mavissakalian M, 1986, J Clin Psych, 47, 117
- Mavissakalian M, 1986, Am J Psych, 143, 1106, 10.1176/ajp.143.9.1106 · DOI
- Mavissakalian M, 1983, Br J Psychiatry, 143, 348, 10.1192/bjp.143.4.348 · DOI
- McDougle C J., 1991, J Clin Psychopharmacol, 11, 175, 10.1097/00004714-199106000-00005 · DOI
- McDougle C J., 1994, Arch Gen Psychiatry, 51, 302, 10.1001/archpsyc.1994.03950040046006 · DOI · Paper page
- 10.1176/ajp.155.11.1570 · DOI
- Michelson L, 1988, Behav Ther, 19, 97, 10.1016/S0005-7894(88)80035-2 · DOI
- Milanfranchi A, 1997, Int Clin Psychopharmacol, 12, 131, 10.1097/00004850-199705000-00002 · DOI
- Mindus P, 1994, J Neuropsychiatry Clin Neurosci, 6, 467, 10.1176/jnp.6.4.467 · DOI
- Misri S, 2000, Canadian Family Physician, 46, 626
- Misri S, 2000, Canadian Journal of Psychiatry‐Revue Canadienne De Psychiatrie, 45, 285, 10.1177/070674370004500309 · DOI
- Modigh K, 1992, J Clin Psychopharmacol, 12, 251, 10.1097/00004714-199208000-00007 · DOI
- Mohr N, 2002, Int Clin Psychopharmacol, 17, 37, 10.1097/00004850-200201000-00006 · DOI
- Möller H J., 2001, J Clin Psychopharmacol, 21, 59, 10.1097/00004714-200102000-00011 · DOI
- Montgomery S A., 1993, Eur Neuropsychopharmacol, 3, 143, 10.1016/0924-977X(93)90266-O · DOI · Paper page
- Montgomery S A., 2001, Int Clin Psychopharmacol, 16, 75, 10.1097/00004850-200103000-00002 · DOI · Paper page
- Moroz G, 1999, J Clin Psychiatry, 60, 604, 10.4088/JCP.v60n0907 · DOI
- Mundo E, 1998, Int Clin Psychopharmacol, 13, 219, 10.1097/00004850-199809000-00005 · DOI
- Mundo E, 2000, Int Clin Psychopharmacol, 15, 69, 10.1097/00004850-200015020-00002 · DOI
- Munjack D J., 1989, J Clin Psychopharmacol, 9, 22
200 of 316 shown
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Self-citationDomschke, K., Stevens, S., Pfleiderer, B., & Gerlach, A. L. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.08.008 · Cited by 580
Tyrer, P., & Baldwin, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69865-6 · Cited by 404
Treatment-resistant anxiety disorders
Bystritsky, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001852 · Cited by 289
Metadata
- Authors
- Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP Task Force on Treatment Guide
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 3
- Issue
- 4
- Pages
- 171-199
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W4205258863
- Cited by
- 167
- References
- 34
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. https://app.cochat.ai/papers/10.3109/15622970209150621
- The paper
- Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP Task Force on Treatment Guide. (2002). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622970209150621
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.